S.a. Joullie International

Metabio Joullie

Les Derives Resiniques Et Terpeniques

Recherches Pharmaceutiques Et Scientifiques

Joullie International

Lucien Lakah

Maurice Joullie

Gabriel Maillard

Christian J Warolin

Yves Robert Pascal

Pierre Muller

Bernard Lahourcade

Christiane Hirigoyen

Compounds of the formula I ##STR1## wherein m and n are 0, 1 or 2, X represents oxygen, imino, benzylimino, or morpholinoethylimino, Y represents CO, CONH, COO or SO.sub.2, and NR.sub.1 R.sub.2 represents a dimethylamino, diethylamino, dipropylamino, dibutylamino, allylamino, isobutenylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, cyclooctylamino, N-methyl N-cyclopentylamino, N-methyl N-cyclohexylamino, N-allyl N-cyclohexylamino, adamantylamino, diethoxyethylamino, dimethylaminoethylamino, dimethylaminopropylamino, N-methyl N-dimethylaminopropyl-amino, benzylamino, 3,4,5-trimethoxybenzylamino, phenethylamino, p-chlorophenethylamino, tetrahydrofurfurylamino, tetrahydropyranylmethylamino, pyrrolidino, isoxazolidinyl, piperidino, 4-hydroxypiperidino, 4-m-chlorophenyl-4-hydroxypiperidino, homopiperidino, 1,2,3,6-tetrahydropyridyl, morpholino, 2-methylmorpholino, 2,6-dimethylmorpholino, 2-morpholinoethylamino, thiamorpholino, piperazino, 4-methylpiperazino, 4-(.alpha.-m-chlorophenyl-benzyl)-piperazino, 4-(3,4,5-trimethoxyphenylaminocarbonyl)-piperazino, 4-(3,4,5-trimethoxyphenylaminocarbonylmethyl)-piperazino, 4-phenylpiperazino, 4-m-trifluoromethylphenyl-piperazino, 4-piperidinocarbonylmethyl-piperazino, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, (7-chloro-4-quinolyl)-amino, 1,2,3,4-tetrahydrobenzoxazinyl or 1,2,3,4-tetrahydro-6-chlorobenzoxazinyl group, and their pharmaceutically acceptable acid addition salts are novel and are therapeutically useful, in particular as tranquillizers, myorelaxants and anticonvulsants.

Therapeutically useful 3,4,5-trimethoxybenzene derivatives

Compounds of the formula I ##STR1## wherein R.sub.1 represents a hydrogen or fluorine atom, and R.sub.2 represents an alkyl group containing 2 to 6 carbon atoms, or a cycloalkyl or cycloalkyl-alkyl group containing 5 to 8 carbon atoms, each of these groups being substituted by one or two hydroxy groups or an oxo group and, if desired, also by a 4-(m-trifluoromethylphenyl)-piperazino or 4-(3-trifluoromethyl-4-fluoro-phenyl)-piperazino group with the proviso that, when R.sub.1 represents a hydrogen atom, R.sub.2 does not represent a monohydroxyalkyl group, and their pharmaceutically acceptable acid addition salts are novel and have therapeutic use, notably in the region of the central nervous system and in the cardiovascular region.

M-Trifluoro-methylphenyl-piperazine

(Carboxymethylthio)acetic acid and its salts provide a mucolytic effect, and the calcium and magnesium salts are of special interest for the field of immune response reactions.

(Carboxymethylthio)acetic acid and salts thereof used as mucolytic agents

(Carboxyalkylthio)acetic acid and their salts provide a mucolytic effect, and the calcium and magnesium salts are of a special interest for the field of immune response reactions.

Mucolytically effective agents

4-Chromanone derivatives of the formula: ##STR1## wherein R represents alkyl of 1 through 6 carbon atoms or alkoxyalkyl of 2 through 6 carbon atoms, are new compounds possessing pharmacological properties and are useful inter alia as vasodilators.

3-Aminomethyl derivatives of 4-chromanone

1-Hydroxy-4-(3'-m.menthen-4'-yl)-benzene, 1-hydroxy-3-methyl-4-(3'-m.menthen-4'-yl)-6-isopropyl-benzene and their sulfonates have antiviral activity against influenza virus and antibacterial activity against gram-positive bacteria.

Phenolic menthene derivatives, therapeutic composition containing same

S-substituted cysteines, alkyl esters of S-substituted cysteines and S-substituted glutathiones in which the substituent on the S atom is allyl, geranyl, cinnamyl, benzylidene-3-butyl, 1-(para-chlorophenyl)ethyl and (pyridyl-3)methyl but excluding S-allyl cysteine bring about a reduction in atheromatic deposits in the aorta of test animals as well as a reduction in hypercholesterolemia and are of low toxicity. They may be used by the conventional routes for the treatment of human atheromatic conditions and disorders of the lipid metabolism.

Growing community of inventors

Paris, France

Lucien Lakah